Journal of Clinical Oncology, Vol 10, 378-382, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study

GP Biti, G Cimino, C Cartoni, SM Magrini, AP Anselmo, RM Enrici, GP Bellesi, A Bosi, G Papa and D Giannarelli
Department of Human Biopathology, University La Sapienza, Rome, Italy.

PURPOSE: To compare the effectiveness of chemotherapy (CHT) with extended-field radiotherapy (RT) in the treatment of early-stage Hodgkin's disease (ESHD), we report an 8-year updated analysis of a study in which treatment with six cycles of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) CHT was randomly compared with extended-field RT. PATIENTS AND METHODS: From August 1979 to December 1982, 89 adult patients with pathologic stage I-IIA Hodgkin's disease (HD) were randomly allocated to receive either RT with mantle field followed by periaortic irradiation (n = 45) or six monthly courses of MOPP CHT (n = 44). RESULTS: All patients in the RT arm and 40 of 44 in the CHT arm achieved complete remission. Twelve relapses occurred in each group. Eight patients treated with MOPP and two of the RT arm died of HD. Three other patients of the CHT group died because of a second cancer. With a median follow-up greater than 8 years, the overall survival rate is significantly higher in the RT than in the CHT group (93% v 56%; P less than .001), whereas the rates of freedom from progression and relapse-free survival (RFS) were similar in the two groups (76% v 64% and 70% v 71%, respectively). Of the 12 patients relapsing after RT, 11 (92%) achieved a second CR, compared with only six of the 12 (50%) in the MOPP group. Analysis of the response rate to salvage treatments showed that the type of relapse in the MOPP group was a prognostic indicator for the achievement of a second CR, whereas in the RT group, a second CR was obtained regardless of the characteristics of the relapses. At 80 months, the probability of survival of relapsing patients calculated from time of relapse was 85% and 15% in the RT and CHT groups, respectively (P = .02). CONCLUSION: We conclude that RT alone is the treatment of choice for adult patients with ESHD with favorable prognostic factors.

This article has been cited by other articles:

				J Franklin, A Pluetschow, M Paus, L Specht, A-P Anselmo, A Aviles, G Biti, T Bogatyreva, G Bonadonna, C Brillant, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials Ann. Onc., December 1, 2006; 17(12): 1749 - 1760. [Abstract] [Full Text] [PDF]

				M. K. Gospodarowicz and R. M. Meyer The Management of Patients with Limited-Stage Classical Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 253 - 258. [Abstract] [Full Text] [PDF]

				G. P. Canellos Chemotherapy Alone for Early Hodgkin's Lymphoma: An Emerging Option J. Clin. Oncol., July 20, 2005; 23(21): 4574 - 4576. [Full Text] [PDF]

				A. Rueda Dominguez, A. Marquez, J. Guma, M. Llanos, J. Herrero, M. A. de las Nieves, J. Miramon, and E. Alba Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study Ann. Onc., December 1, 2004; 15(12): 1798 - 1804. [Abstract] [Full Text] [PDF]

				E. Duhmke, J. Franklin, M. Pfreundschuh, S. Sehlen, N. Willich, U. Ruhl, R.-P. Muller, P. Lukas, A. Atzinger, U. Paulus, et al. Low-Dose Radiation Is Sufficient for the Noninvolved Extended-Field Treatment in Favorable Early-Stage Hodgkin's Disease: Long-Term Results of a Randomized Trial of Radiotherapy Alone J. Clin. Oncol., June 1, 2001; 19(11): 2905 - 2914. [Abstract] [Full Text] [PDF]

				K. H. Backstrand, A. K. Ng, R. W. Takvorian, E. L. Jones, D. C. Fisher, B. J. Molnar-Griffin, B. Silver, N. J. Tarbell, and P. M. Mauch Results of a Prospective Trial of Mantle Irradiation Alone for Selected Patients With Early-Stage Hodgkin's Disease J. Clin. Oncol., February 1, 2001; 19(3): 736 - 741. [Abstract] [Full Text] [PDF]

				D. C. Linch, R. G. Gosden, T. Tulandi, S.-L. Tan, and S. L. Hancock Hodgkin's Lymphoma: Choice of Therapy and Late Complications Hematology, January 1, 2000; 2000(1): 205 - 221. [Abstract] [Full Text] [PDF]

				A. K. Ng, J. C. Weeks, P. M. Mauch, and K. M. Kuntz Decision Analysis on Alternative Treatment Strategies for Favorable-Prognosis, Early-Stage Hodgkin's Disease J. Clin. Oncol., November 1, 1999; 17(11): 3577 - 3585. [Abstract] [Full Text] [PDF]

				A. C. Aisenberg Problems in Hodgkin's Disease Management Blood, February 1, 1999; 93(3): 761 - 779. [Full Text] [PDF]

				A. Wirth, M. Chao, J. Corry, C. Laidlaw, K. Yuen, G. Ryan, D. Byram, S. Davis, J. Kiffer, G. Quong, et al. Mantle Irradiation Alone for Clinical Stage I-II Hodgkin's Disease: Long-Term Follow-Up and Analysis of Prognostic Factors in 261 Patients J. Clin. Oncol., January 1, 1999; 17(1): 230 - 230. [Abstract] [Full Text] [PDF]

				A. K. Ng, J. C. Weeks, P. M. Mauch, and K. M. Kuntz Laparotomy Versus No Laparotomy in the Management of Early-Stage, Favorable-Prognosis Hodgkin's Disease: A Decision Analysis J. Clin. Oncol., January 1, 1999; 17(1): 241 - 241. [Abstract] [Full Text] [PDF]

				U. Baccarani, B. J. Carroll, J. R. Hiatt, A. Donini, G. Terrosu, R. Decker, M. Chandra, F. Bresadola, and E. H. Phillips Comparison of Laparoscopic and Open Staging in Hodgkin Disease Arch Surg, May 1, 1998; 133(5): 517 - 522. [Abstract] [Full Text] [PDF]

				P. S. Multani and M. L. Grossbard Staging Laparotomy in the Management of Hodgkin's Disease: Is it Still Necessary? Oncologist, February 1, 1996; 1(1): 41 - 55. [Abstract] [Full Text] [PDF]

				E. A. Perez, S. A. Rosenthal, V. T. DeVita, and S. M. Hubbard Hodgkin's Disease N. Engl. J. Med., July 29, 1993; 329(5): 361 - 362. [Full Text]

				V. T. DeVita and S. M. Hubbard Hodgkin's Disease N. Engl. J. Med., February 25, 1993; 328(8): 560 - 565. [Full Text]